{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:09:40Z","timestamp":1790096980165,"version":"4.0.1"},"reference-count":72,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012544","name":"China Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012544","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007300","name":"China Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007300","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.drudis.2026.104776","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T16:07:45Z","timestamp":1787155665000},"page":"104776","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["mRNA therapeutics for restoring immune tolerance in autoimmune diseases"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8225-456X","authenticated-orcid":false,"given":"Moncef","family":"Zouali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104776_b0005","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41584-025-01291-0","article-title":"Immune-cell profiling to guide stratification and treatment of patients with rheumatic diseases","volume":"21","author":"Rao","year":"2025","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.drudis.2026.104776_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101566","article-title":"Harnessing mRNA-lipid nanoparticles as innovative therapies for autoimmune diseases","volume":"33","author":"Razavi","year":"2025","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.drudis.2026.104776_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2025.103753","article-title":"Advances in RNA therapy for the treatment of autoimmune diseases","volume":"24","author":"Zhang","year":"2025","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.drudis.2026.104776_b0020","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1626082","article-title":"Autoimmune disease: genetic susceptibility, environmental triggers, and immune dysregulation. Where can we develop therapies?","volume":"16","author":"Kumar","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2026.104776_b0025","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.clim.2004.08.019","article-title":"B-lymphocytes, innate immunity, and autoimmunity","volume":"114","author":"Viau","year":"2005","journal-title":"Clin Immunol"},{"key":"10.1016\/j.drudis.2026.104776_b0030","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1172\/JCI0214941","article-title":"Activation and inhibition of lymphocytes by costimulation","volume":"109","author":"Frauwirth","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2026.104776_b0035","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: advances and mechanistic insights","volume":"20","author":"Lee","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104776_b0040","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41573-024-00959-8","article-title":"Sequential immunotherapy: towards cures for autoimmunity","volume":"23","author":"Ramirez-Valle","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104776_b0045","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.ard.2025.01.023","article-title":"Efficacy of Janus kinase inhibitors in immune-mediated inflammatory diseases a systematic literature review informing the 2024 update of an international consensus statement","volume":"84","author":"Konzett","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.drudis.2026.104776_b0050","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/d41573-025-00061-7","article-title":"Trends in the drug target landscape for autoimmune diseases","volume":"24","author":"Fauconnier","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104776_b0055","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ana.25119","article-title":"B-cell therapy for multiple sclerosis: entering an era","volume":"83","author":"Greenfield","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1016\/j.drudis.2026.104776_b0060","article-title":"Very low doses of rituximab in autoimmune hemolytic anemia\u2014an open-label, phase II pilot trial","volume":"11","author":"Moser","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.drudis.2026.104776_b0065","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.tibtech.2024.01.006","article-title":"Engineered immune cells as therapeutics for autoimmune diseases","volume":"42","author":"Zouali","year":"2024","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.drudis.2026.104776_b0070","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.crohns.2011.10.007","article-title":"Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases","volume":"6","author":"Guerra","year":"2012","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.drudis.2026.104776_b0075","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics\u2014developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104776_b0080","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/nature16962","article-title":"Expanding antigen-specific regulatory networks to treat autoimmunity","volume":"530","author":"Clemente-Casares","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104776_b0085","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104776_b0090","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","article-title":"The clinical progress of mRNA vaccines and immunotherapies","volume":"40","author":"Barbier","year":"2022","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.drudis.2026.104776_b0095","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104776_b0100","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jconrel.2021.08.040","article-title":"Genetic in situ engineering of myeloid regulatory cells controls inflammation in autoimmunity","volume":"339","author":"Parayath","year":"2021","journal-title":"J Control Release"},{"key":"10.1016\/j.drudis.2026.104776_b0105","doi-asserted-by":"crossref","first-page":"e1510","DOI":"10.1002\/wrna.1510","article-title":"The dynamic RNA modification 5-methylcytosine and its emerging role as an epitranscriptomic mark","volume":"10","author":"Trixl","year":"2019","journal-title":"Wiley Interdiscip Rev: RNA"},{"key":"10.1016\/j.drudis.2026.104776_b0110","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","article-title":"Innate immune mechanisms of mRNA vaccines","volume":"55","author":"Verbeke","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.drudis.2026.104776_b0115","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41586-021-03275-y","article-title":"BNT162b vaccines protect rhesus macaques from SARS-CoV-2","volume":"592","author":"Vogel","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104776_b0120","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.ymthe.2017.03.001","article-title":"Current progress in non-viral RNAi-based delivery strategies to lymphocytes","volume":"25","author":"Mizrahy","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.drudis.2026.104776_b0125","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1126\/science.aay3638","article-title":"A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis","volume":"371","author":"Krienke","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.drudis.2026.104776_b0130","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2311276120","article-title":"Biomimetic noncationic lipid nanoparticles for mRNA delivery","volume":"120","author":"Wang","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2026.104776_b0135","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/mt.2010.85","article-title":"Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms","volume":"18","author":"Akinc","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.drudis.2026.104776_b0140","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jconrel.2024.09.020","article-title":"LNP-mRNA vaccine prevents type 1 diabetes in non-obese diabetes mice","volume":"375","author":"Chen","year":"2024","journal-title":"J Control Release"},{"key":"10.1016\/j.drudis.2026.104776_b0145","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1006\/jaut.2000.0380","article-title":"Driver clones and determinant spreading","volume":"14","author":"Sercarz","year":"2000","journal-title":"J Autoimmun"},{"key":"10.1016\/j.drudis.2026.104776_b0150","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41584-024-01201-w","article-title":"Antigen-specific immunotherapies for autoimmune disease","volume":"21","author":"Buckner","year":"2025","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.drudis.2026.104776_b0155","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3390\/cells14141085","article-title":"Inverse vaccination for autoimmune diseases: insights into the role of B lymphocytes","volume":"14","author":"Zouali","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.drudis.2026.104776_b0160","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(07)60750-8","article-title":"Inflammatory bowel disease: cause and immunobiology","volume":"369","author":"Baumgart","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2026.104776_b0165","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1038\/s41467-018-06936-1","article-title":"Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes","volume":"9","author":"Veiga","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104776_b0170","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3389\/fphar.2019.00308","article-title":"Glucocorticoid-induced leucine zipper: a novel anti-inflammatory molecule","volume":"10","author":"Bereshchenko","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2026.104776_b0175","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.3390\/ph16091270","article-title":"Tolerogenic lipid nanoparticles for delivering self-antigen mRNA for the treatment of experimental autoimmune encephalomyelitis","volume":"16","author":"Gomi","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.drudis.2026.104776_b0180","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1626085","article-title":"Navigating the manufacturing, testing and regulatory complexities of regulatory T cells for adoptive cell therapy","volume":"16","author":"Pikor","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2026.104776_b0185","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1038\/s41467-022-31130-9","article-title":"Selective activation and expansion of regulatory T cells using lipid encapsulated mRNA encoding a long-acting IL-2 mutein","volume":"13","author":"de Picciotto","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104776_b0190","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nri2785","article-title":"FOXP3+ regulatory T cells in the human immune system","volume":"10","author":"Sakaguchi","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.drudis.2026.104776_b0195","doi-asserted-by":"crossref","first-page":"18575","DOI":"10.1073\/pnas.1000400107","article-title":"Cell-permeable Foxp3 protein alleviates autoimmune disease associated with inflammatory bowel disease and allergic airway inflammation","volume":"107","author":"Choi","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2026.104776_b0200","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay6422","article-title":"Gene editing to induce FOXP3 expression in human CD4+ T cells leads to a stable regulatory phenotype and function","volume":"12","author":"Honaker","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.drudis.2026.104776_b0205","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV vector immunogenicity in humans: a long journey to successful gene transfer","volume":"28","author":"Costa Verdera","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.drudis.2026.104776_b0210","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2026.104776_b0215","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3389\/fimmu.2020.00176","article-title":"Adoptive cell therapy targeting neoantigens: a frontier for cancer research","volume":"11","author":"Wang","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2026.104776_b0220","doi-asserted-by":"crossref","first-page":"10179","DOI":"10.1021\/acs.nanolett.3c02573","article-title":"mRNA lipid nanoparticles for ex vivo engineering of immunosuppressive T cells for autoimmunity therapies","volume":"23","author":"Thatte","year":"2023","journal-title":"Nano Lett"},{"key":"10.1016\/j.drudis.2026.104776_b0225","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1126\/science.ads8473","article-title":"In vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"388","author":"Hunter","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.drudis.2026.104776_b0230","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease\u2014a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104776_b0235","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2217\/nnm.12.164","article-title":"Assessment of tumor antigen-loaded solid lipid nanoparticles as an efficient delivery system for dendritic cell engineering","volume":"8","author":"Bhargava","year":"2013","journal-title":"Nanomedicine (Lond)"},{"key":"10.1016\/j.drudis.2026.104776_b0240","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.immuni.2022.05.010","article-title":"Genetic tracing reveals transcription factor Foxp3-dependent and Foxp3-independent functionality of peripherally induced Treg cells","volume":"55","author":"Van der Veeken","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.drudis.2026.104776_b0245","doi-asserted-by":"crossref","first-page":"32017","DOI":"10.1073\/pnas.2016451117","article-title":"Tolerogenic nanoparticles suppress central nervous system inflammation","volume":"117","author":"Kenison","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2026.104776_b0250","doi-asserted-by":"crossref","DOI":"10.1172\/JCI178949","article-title":"Targeting aryl hydrocarbon receptor functionally restores tolerogenic dendritic cells derived from patients with multiple sclerosis","volume":"134","author":"Fondelli","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2026.104776_b0255","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41551-025-01373-0","article-title":"Generation of tolerogenic antigen-presenting cells in vivo via the delivery of mRNA encoding PDL1 within lipid nanoparticles","volume":"9","author":"Liu","year":"2025","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.drudis.2026.104776_b0260","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1056\/NEJMoa2113017","article-title":"Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase","volume":"385","author":"El Sahly","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104776_b0265","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/s41591-024-02955-2","article-title":"An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2\/3 randomized trial","volume":"30","author":"Saraf","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2026.104776_b0270","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3390\/vaccines12030318","article-title":"Self-amplifying RNA: a second revolution of mRNA vaccines against COVID-19","volume":"12","author":"Silva-Pilipich","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.drudis.2026.104776_b0275","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ymthe.2019.09.009","article-title":"A trans-amplifying RNA vaccine strategy for induction of potent protective immunity","volume":"28","author":"Beissert","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.drudis.2026.104776_b0280","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.tibtech.2023.05.007","article-title":"Rise of the RNA machines\u2014self-amplification in mRNA vaccine design","volume":"41","author":"Comes","year":"2023","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.drudis.2026.104776_b0285","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41541-025-01097-x","article-title":"Recent advances and perspectives on the development of circular RNA cancer vaccines","volume":"10","author":"Gong","year":"2025","journal-title":"npj Vaccines"},{"key":"10.1016\/j.drudis.2026.104776_b0290","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2302191120","article-title":"Circular RNA vaccine induces potent T cell responses","volume":"120","author":"Amaya","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2026.104776_b0295","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41541-024-00963-4","article-title":"CircRNA based multivalent neuraminidase vaccine induces broad protection against influenza viruses in mice","volume":"9","author":"Yue","year":"2024","journal-title":"npj Vaccines"},{"key":"10.1016\/j.drudis.2026.104776_b0300","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s41586-023-06127-z","article-title":"Algorithm for optimized mRNA design improves stability and immunogenicity","volume":"621","author":"Zhang","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104776_b0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115190","article-title":"mRNA delivery systems for cancer immunotherapy: lipid nanoparticles and beyond","volume":"206","author":"Estape Senti","year":"2024","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.drudis.2026.104776_b0310","first-page":"523","article-title":"Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: implication for therapeutic RNA development","volume":"10","author":"Karik\u00f3","year":"2007","journal-title":"Curr Opin Drug Discov Devel"},{"key":"10.1016\/j.drudis.2026.104776_b0315","doi-asserted-by":"crossref","first-page":"6071","DOI":"10.1016\/j.cell.2024.08.025","article-title":"Neoself-antigens are the primary target for autoreactive T cells in human lupus","volume":"187","author":"Mori","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2026.104776_b0320","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s12276-023-00999-x","article-title":"Knife\u2019s edge: balancing immunogenicity and reactogenicity in mRNA vaccines","volume":"55","author":"Lee","year":"2023","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.drudis.2026.104776_b0325","doi-asserted-by":"crossref","first-page":"6181","DOI":"10.1038\/s41467-024-50656-8","article-title":"Long-term risk of autoimmune diseases after mRNA-based SARS-CoV2 vaccination in a Korean, nationwide, population-based cohort study","volume":"15","author":"Jung","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104776_b0330","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202312026","article-title":"Physicochemical targeting of lipid nanoparticles to the lungs induces clotting: mechanisms and solutions","volume":"36","author":"Omo-Lamai","year":"2024","journal-title":"Adv Mater"},{"key":"10.1016\/j.drudis.2026.104776_b0335","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/s41563-024-01867-3","article-title":"Accelerating ionizable lipid discovery for mRNA delivery using machine learning and combinatorial chemistry","volume":"23","author":"Li","year":"2024","journal-title":"Nat Mater"},{"key":"10.1016\/j.drudis.2026.104776_b0340","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41563-024-01934-9","article-title":"Lipid discovery for mRNA delivery guided by machine learning","volume":"23","author":"Van der Meel","year":"2024","journal-title":"Nat Mater"},{"key":"10.1016\/j.drudis.2026.104776_b0345","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nri2153","article-title":"Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease","volume":"7","author":"Miller","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.drudis.2026.104776_b0350","doi-asserted-by":"crossref","first-page":"E156","DOI":"10.1073\/pnas.1408686111","article-title":"Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance","volume":"112","author":"Maldonado","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2026.104776_b0355","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201801419","article-title":"Engineering immune tolerance with biomaterials","volume":"8","author":"Gammon","year":"2019","journal-title":"Adv Healthc Mater"},{"key":"10.1016\/j.drudis.2026.104776_b0360","article-title":"Robust anti-tumor T cell response with efficient intratumoral infiltration by nanodisc cancer immunotherapy","volume":"3","author":"Kuai","year":"2020","journal-title":"Adv Ther (Weinh)"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626001819?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626001819?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:22:54Z","timestamp":1790094174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626001819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":72,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1359644626001819"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104776","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"mRNA therapeutics for restoring immune tolerance in autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104776","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104776"}}